SMF Schweizerisches Medizin-Forum 1424-4020 1424-3784 EMH Schweizerischer Ärzteverlag AG Farnsburgerstrasse 8 CH-4132 Muttenz 08532 10.4414/smf.2020.08532 Wie deuten Sie diesen Befund? Allergologie / Immunologie Angiologie Gynäkologie und Geburtshilfe Hämatologie Labormedizin Syndrome Interprétation du dosage des anticorps anti-phospholipides Nozic Adnan adnan.nozic@hospvd.ch Bugnon 46 | Lausanne | 1005 | SWITZERLAND Burger Raphael Centre universitaire hospitalier vaudois (CHUV) Service de médecine interne Alberio Lorenzo Centre universitaire hospitalier vaudois (CHUV), Service et laboratoire central d'hématologie Ribi Camillo Centre universitaire hospitalier vaudois (CHUV), Service d’immunologie et allergie 04 11 2020 20 4546 648 650 Copyright: EMH Schweizerischer Ärzteverlag AG 2020 EMH Schweizerischer Ärzteverlag AG "Swiss Medical Forum" is an open access publication of EMH published in accordance with the terms of the Creative Commons licence attribution - NonCommercial - NoDerivatives 4.0 International. You are free to share, copy and redistribute the material in any medium or format under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. NonCommercial — You may not use the material for commercial purposes. NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material. "Non-commercial" means not primarily intended for or directed towards commercial advantage or monetary compensation. The incorporation of publications in commercial products, the use of publications to advertise for commercial products or services and any other usage that directly or indirectly pursues commercial interests is subject to the express previous consent of the publishing house as part of a written agreement. Please send us your request in writing. Exact indication of the publication from which you would like to reproduce material and detailed information about its intended use help to facilitate and expedite request processing. <p>Antiphospholipid syndrome (APS) is an autoimmune disease characterized by thrombotic or obstetrical events that occur in patients with plasma antiphospholipid antibodies. These antibodies are a heterogeneous group, directed against phospholipids, inducing a procoagulant state that can reach any vascular territory and which increase the risk of excessive blood clotting. Three types of antibodies are relevant because of their clinical implication: lupus anticoagulant (LA), anti-beta2 glycoprotein I antibodies (anti-ß2GPI) and anticardiolipin antibodies (aCL). LA is detected through coagulation based assays. Testing for aCL and anti-ß2GPI is based on enzyme-linked-immunosorbent assay (ELISA) or chemiluminescence immunoassay (CLIA). In order to establish the diagnosis of APS at least one of these tests must be positive, and the same test must be repeated 12 weeks later to confirm the presence of aPL. It is important to note that anticoagulant therapy affects LA search, but not for aCL and anti-ß2GPI. Finally, the aPL levels could be elevated in a healthy population and testing should be reserved for situations with high clinical probability. Once the diagnosis of APS is established, in order to better target the treatment, one should determine the risk of thrombotic event recurrence according to the aPL profile.</p>